Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idiotype-pulsed allogeneic dendritic cells
- Development stage
- Phase 2
- Lead developer
- Stanford University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intravenous, Intradermal
01
Overview
Idiotype-pulsed allogeneic dendritic cells are a form of cell-based cancer immunotherapy in which donor-derived (allogeneic) dendritic cells are loaded ex vivo with an autologous tumor-specific immunoglobulin (idiotype) protein. This vaccine is designed to stimulate the patient's immune system to recognize and attack malignant B-cells expressing the same idiotype, particularly in diseases such as multiple myeloma and B-cell lymphomas. The mechanism involves presenting tumor-specific antigens via major histocompatibility complex (MHC) molecules on the surface of activated dendritic cells, thereby priming T-cell responses against the cancer. Clinical studies have shown that this approach is safe and can induce immune responses; however, clinical efficacy has been limited and further optimization is needed[1][2][3][4][5][9].
- Other names
- allogeneic dendritic cell-myeloma idiotype vaccineId-pulsed alloDCidiotype-pulsed alloDC
Beyond the preview
Go deeper on idiotype-pulsed allogeneic dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idiotype-pulsed allogeneic dendritic cells.